Coeptis Therapeutics, Inc.
NASDAQ:COEP · NASDAQ Capital Market
+$0.73 today
Vol 0.13M · Avg 0.05M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $5.2M |
| Short-term Investments | $50.6K |
| Receivables | $15.3K |
| Other Current | $631.1K |
| Total Current Assets | $5.9M |
| PP&E (Net) | $89.3K |
| Intangible Assets | $316.1K |
| Long-term Investments | $13.2M |
| Other Non-current | $313.9K |
| Total Non-current Assets | $13.9M |
| Total Assets | $19.8M |
Analysis
Selected assets total $19.8M for Latest. The largest visible component is Long-term Investments at $13.2M, about 66.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.7M +964.8% | $532.9K -63.7% | $1.5M -61.2% | $3.8M +73.9% | $2.2M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $676.6K | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $7.3K | $0 -100.0% | $39.0K +382.7% | $8.1K | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $7.4M +599.2% | $1.1M -39.9% | $1.7M -55.6% | $3.9M +80.9% | $2.2M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $18.4K -69.2% | $59.8K -45.1% | $108.9K +52.4% | $71.5K +124.3% | $31.9K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $361.3K -33.3% | $541.9K -78.8% | $2.6M -28.1% | $3.6M -22.0% | $4.6M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $7.9M +38.1% | $5.7M +62.6% | $3.5M | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $4.3M +171.7% | $1.6M +888.2% | $158.3K -54.5% | $348.3K -92.4% | $4.6M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $12.5M +59.0% | $7.9M +24.3% | $6.3M +59.1% | $4.0M -13.3% | $4.6M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $19.8M +122.7% | $8.9M +10.4% | $8.1M +2.0% | $7.9M +17.0% | $6.8M | $13.3B | $11.9B | $10.6B |
| Account Payables | $888.8K -30.0% | $1.3M -10.6% | $1.4M +1333.7% | $99.0K -26.2% | $134.1K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $118.9K -90.0% | $1.2M +17.3% | $1.0M -46.4% | $1.9M -21.7% | $2.4M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $599.5K | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $161.1K -87.4% | $1.3M +129.6% | $556.0K +205.5% | $182.0K -8.6% | $199.1K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $1.8M -60.8% | $4.5M +51.0% | $3.0M +37.6% | $2.2M -21.4% | $2.8M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $150.0K +0.0% | $150.0K +0.0% | $150.0K +0.0% | $150.0K -90.9% | $1.6M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $167.6K -53.3% | $359.3K -35.5% | $557.2K -50.5% | $1.1M | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $317.6K -39.9% | $528.1K -31.3% | $768.4K -40.4% | $1.3M -21.8% | $1.6M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $2.1M -58.6% | $5.0M +34.2% | $3.8M +8.5% | $3.5M -21.6% | $4.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $575 +171.2% | $212 -94.0% | $3.5K +80.5% | $2.0K -44.9% | $3.5K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$110.0M -11.9% | -$98.2M -12.5% | -$87.4M -32.2% | -$66.1M -139.9% | -$27.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 +100.0% | -$1.6M | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $506.2K -25.8% | $682.1K | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $17.8M +359.1% | $3.9M -10.4% | $4.3M -3.1% | $4.5M +89.5% | $2.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $268.9K -80.8% | $1.4M +14.3% | $1.2M -40.5% | $2.1M -49.6% | $4.1M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$5.4M -724.1% | $866.2K +453.7% | -$244.9K +85.9% | -$1.7M -191.2% | $1.9M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$204.42M
Century Therapeutics, Inc.
NASDAQ:IPSC
$198.24M
Equillium, Inc.
NASDAQ:EQ
$108.34M
OS Therapies Incorporated
AMEX:OSTX
$85.96M
Cue Biopharma, Inc.
NASDAQ:CUE
$74.79M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$68.62M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$65.00M
Telomir Pharmaceuticals, Inc. Common Stock
TELO
$48.82M
Senti Biosciences, Inc.
SNTI
$24.50M
Medicus Pharma Ltd. Common Stock
MDCX
$10.08M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does COEP have?
Coeptis Therapeutics, Inc. (COEP) reported $5.67M in cash and equivalents in fiscal 2025.
How much debt does COEP carry?
Coeptis Therapeutics, Inc. (COEP) reported $268,875.00 of total debt, with net debt of -$5,405,427.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.